“While it took some time to get to the right approach with KLK2, these results make the effort well worth it. True innovation. A novel and ideal target for a solid tumor TCE with a therapeutic index that breaks new ground. Congratulations to the brave trailblazers on the J&J prostate cancer team. Huge kudos to Chuck Drake as the champion of this target. Looking forward to seeing the combo data!!“
More posts featuring Prostate Cancer on OncoDaily.